Myelodysplastic syndrome.
Indian J Pediatr
;
2008 Jul; 75(7): 729-32
Article
Dans Anglais
| IMSEAR
| ID: sea-82211
ABSTRACT
Pediatric myelodysplastic syndrome (MDS), though rare, constitutes a distinct entity quite different from adult MDS. They have unique clinical features, aggressive clinical course with an overall mean survival of only 9.9 months. A pediatric approach to the WHO classification has become necessary since the WHO classification of MDS has failed to address the uniqueness of pediatric MDS. A new prognostic system also needs to be evolved since the international prognostic system has limited prognostic impact in children. Intensive chemotherapy such as the one used in de novo-acute myeloid leukemia (AML) leads to complete remission in some children and this may be the treatment of choice in pediatric MDS.
Texte intégral:
Disponible
Indice:
IMSEAR (Asie du Sud-Est)
Sujet Principal:
Pronostic
/
Syndromes myélodysplasiques
/
Humains
/
Leucémie aigüe myéloïde
/
Enfant
/
Facteurs âges
/
Diagnostic différentiel
Type d'étude:
Etude diagnostique
/
Étude pronostique
langue:
Anglais
Texte intégral:
Indian J Pediatr
Année:
2008
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS